Complement Therapeutics Appoints Dr. Muhammad Ali Memon as Chief Medical Officer
Portfolio - People | Nov 26, 2024 | Biogeneration Ventures (BGV)
Complement Therapeutics GmbH (CTx), an emerging biotechnology firm headquartered in Germany, has appointed Dr. Muhammad Ali Memon as its new Chief Medical Officer, effective from January 2025. Dr. Memon, an accomplished ophthalmologist, brings a wealth of clinical development experience from his previous role at AAVantgarde Bio and other prestigious institutions. His appointment signals a significant step as the company focuses on advancing its pioneering therapeutic candidate, CTx001, towards clinical trials. CTx001, a single-dose gene therapy, aims to address Geographic Atrophy (GA) associated with age-related macular degeneration, a condition with limited treatment options. Complement Therapeutics, a spinout from the University of Manchester, leverages cutting-edge research to develop therapies targeting the complement system. The company's strategic focus includes the launch of CTx001 and the development of the Complement Precision Medicine platform for precise disease diagnostics and monitoring.
Sectors
- Biotechnology
- Pharmaceuticals
Geography
- Germany – Complement Therapeutics is headquartered in Munich, Germany, making it a significant geographical location for this article.
- United Kingdom – The company has roots as a spinout from the University of Manchester and has subsidiaries and research labs in the UK.
Industry
- Biotechnology – The article revolves around Complement Therapeutics, a preclinical stage biotechnology company focused on novel therapeutics for complement-mediated diseases.
- Pharmaceuticals – The development and potential clinical trials of CTx001, a gene therapy for Geographic Atrophy, fall under the pharmaceutical industry.
Financials
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Complement Therapeutics GmbH | Target Company | Company | A biotechnology company focusing on complement-mediated diseases. |
| Dr. Muhammad Ali Memon | Chief Medical Officer Appointee | Person | A qualified ophthalmologist appointed as Chief Medical Officer of Complement Therapeutics. |
| AAVantgarde Bio | Previous Employer | Company | Dr. Memon's previous employer where he served as Vice President, Clinical Science and Safety. |
| Biogeneration Ventures | Private Equity Firm | Company | The private equity firm with a stake in Complement Therapeutics. |